ArticleEuropean journal of nuclear medicine and molecular imaging2022
Investigating ultra-low-dose total-body [18F]-FDG PET/CT in colorectal cancer: initial experience.
Article in European journal of nuclear medicine and molecular imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 64 citations in OpenAlex.
- From sensitivity gain to clinical decisions: total-body and long-axial-field-of-view PET/CT for diagnosis and image-based management in oncology and systemic disease.Annals of nuclear medicine · 2026Review
- Coronary artery disease imaging with total-body PET.The British journal of radiology · 2026Review
- A rapid total-body PET imaging approach for pediatric patients using non-attenuation-corrected PET scans.EJNMMI physics · 2026Article
- Significant dose reduction employing dual-low-dose PET/CT in pediatric lymphoma: maintaining diagnostic, staging, and response-assessing efficacy.European radiology · 2026Article
- Ultra-low dose imaging in a standard axial field-of-view PET.EJNMMI reports · 2025Article
- Eliminating the second CT scan of dual-tracer total-body PET/CT via deep learning-based image synthesis and registration.European journal of nuclear medicine and molecular imaging · 2025Article
- Leveraging small voxel with optimal acquisition time for [European journal of nuclear medicine and molecular imaging · 2025Article
- A digital twin of the Biograph Vision Quadra long axial field of view PET/CT: Monte Carlo simulation and image reconstruction framework.EJNMMI physics · 2025Article
- Predictive role of [EJNMMI reports · 2024Article
- Performance Characteristics of a New Generation 148-cm Axial Field-of-View uMI Panorama GS PET/CT System with Extended NEMA NU 2-2018 and EARL Standards.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Comparative benefits of Ki and SUV images in lesion detection during PET/CT imaging.EJNMMI research · 2024Article
- Performance and application of the total-body PET/CT scanner: a literature review.EJNMMI research · 2024Review
- Phantom study and clinical application of total-bodyEJNMMI physics · 2024Article
- QUALIPAED-A retrospective quality control study evaluating pediatric long axial field-of-view low-dose FDG-PET/CT.Frontiers in nuclear medicine · 2024Article
- Head-to-head intra-individual comparison of total-body 2-[European radiology · 2023Article
- Image Quality and Quantitative PET Parameters of Low-Dose [Diagnostics (Basel, Switzerland) · 2023Article
- Quantitation of dynamic total-body PET imaging: recent developments and future perspectives.European journal of nuclear medicine and molecular imaging · 2023Review
- A proper protocol for routineEJNMMI physics · 2023Article
- Sub-minute acquisition with deep learning-based image filter in the diagnosis of colorectal cancers using total-bodyEJNMMI research · 2023Article
- An exploration of the feasibility and clinical value of half-dose 5-h total-bodyEuropean journal of nuclear medicine and molecular imaging · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study was to evaluate the effects of an ultra-low dose of [18F]-FDG on the image quality of total-body PET/CT and its lesion detectability in colorectal cancer (CRC).
methodsSixty-two CRC patients who underwent total-body PET/CT (uEXPLORER, United Imaging Healthcare, Shanghai, China) with an ultra-low dose (0.37 MBq/kg) of [18F]-FDG were enrolled in this retrospective study. The PET images were reconstructed with the entire 15-min dataset first and then split into 13-, 8-, 5-, 4-, 3-, 2-, and 1-min duration groups to simulate fast scanning images. For simplicity, the images reconstructed with the data from 15 to 1 min were referred to as G15, G13, and so on until G1. Subjective image quality was assessed with 5-point Likert scales. The objective image quality parameters included the SUVmax, SUVmean, and signal-to-noise ratio (SNR) of the liver and blood pool and the SUVmax and tumor-to-background ratio (TBR) of the lesions. G15 served as the control to evaluate lesion detectability.
resultsA total of 62 patients (43 men, 19 women; age 41-88, mean ± SD 64.0 ± 10.9 years) with 64 CRC primary tumor lesions and 10 low-grade intraepithelial neoplasia (LGIN) lesions were enrolled in this study. The subjective scores were highest for G15 (4.5 ± 0.5) and then decreased from G13 (4.3 ± 0.4) to G8 (3.7 ± 0.5). The liver SNR increased with the extension of acquisition time from G8 (17.2 ± 2.8) to G13 (20.6 ± 3.4) and G15 (21.9 ± 3.4). The liver SNR of G8 was not significantly different from that of G13 (p = 0.15) and was significantly different from that of G15 (p = 0.001). All 64 CRC lesions could be identified in all image groups, even on G1. One of ten LGINs was missed on G1, G2, and G3, and one LGIN was missed on G1, G2, G3, and G4. G15 served as the control, and 100% (48/48) lymph nodes could be found on G13 and G8 compared to 93.8% (45/48) lymph nodes on G5 and G4, 85.4% (41/48) lymph nodes on G3, 81.3% (39/48) lymph nodes on G2, and 77.1% (37/48) lymph nodes on G1. For liver metastases, there were no missed liver lesions on G13 and G8 and 3, 4, 6, 7, and 9 missed liver lesions on G5, G4, G3, G2, and G1, respectively. For other areas of metastasis, including the lung, peritoneum, and ovaries, there were no missed lesions in any group.
conclusionsTotal-body PET/CT with an ultra-low dose of [18F]-FDG can maintain satisfactory image quality and lesion detectability in CRC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.